Revolution Medicines' Daraxonrasib Shows Promising Results in Pancreatic Cancer Trials
STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
Stat
Image: Stat
An experimental drug, daraxonrasib, developed by Revolution Medicines, has shown unprecedented results in treating pancreatic cancer, with patients living nearly twice as long compared to those receiving standard chemotherapy, as reported at the American Society of Clinical Oncology meeting.
- 01Daraxonrasib is an experimental targeted drug for pancreatic cancer.
- 02Patients taking daraxonrasib lived nearly twice as long as those on standard chemotherapy.
- 03The clinical trial results were presented at the American Society of Clinical Oncology annual meeting.
- 04Rachna Shroff, a pancreatic cancer expert, expressed deep emotional impact from the results.
- 05The study's findings were published in the New England Journal of Medicine.
Advertisement
In-Article Ad
At the American Society of Clinical Oncology annual meeting, Rachna Shroff, a physician at the University of Arizona Cancer Center, shared groundbreaking results from a clinical trial of daraxonrasib, an experimental drug by Revolution Medicines. Patients treated with daraxonrasib lived almost twice as long as those receiving standard chemotherapy, marking a significant advancement in pancreatic cancer treatment. Shroff, who has treated pancreatic cancer for 16 years, described the results as incredibly impactful, even moving her to tears. The detailed findings were published in the New England Journal of Medicine, highlighting the potential of daraxonrasib to change treatment protocols for this challenging disease.
Advertisement
In-Article Ad
The results of the daraxonrasib trial could lead to a significant shift in treatment practices for pancreatic cancer, potentially improving patient outcomes.
Advertisement
In-Article Ad
Reader Poll
What do you think about the potential of daraxonrasib for pancreatic cancer treatment?
Connecting to poll...
Read the original article
Visit the source for the complete story.